Byetta (exenatide) is a prescription drug that’s used to treat type 2 diabetes. Byetta can cause side effects that range from mild to serious. Examples include nausea and vomiting. The active ...

This morning Amylin Pharmaceuticals,Eli Lilly and Alkermes announced the highly anticipated test results on their once-a-week, Type 2 diabetes drug. One analyst recently called this the most important ...

Amylin Pharmaceuticals is scrambling, unsuccessfully, to create a silver lining for its battered diabetes drug Byetta. The pharmaceutical company released a study at the European Association for the ...

SAN DIEGO (AP) -- Diabetes drug maker Amylin Pharmaceuticals Inc. said Thursday that sales of its new drug Bydureon totaled $6.9 million in the first quarter, missing analysts' estimates. Amylin took ...

Byetta (exenatide) is a prescription drug that’s used to treat type 2 diabetes in adults. This drug can interact with other medications and some supplements. For example, Byetta can interact with ...

Shares of both Eli Lilly and Amylin Pharmaceuticals rose Tuesday after the partners on diabetes drug Byetta told physicians they could begin writing new Byetta prescriptions for diabetes patients. Two ...

SAN DIEGO and INDIANAPOLIS, Oct. 19, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration ...

PHILADELPHIA--Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced new clinical data from the European Exenatide (EUREXA) study that showed treatment with BYETTA® (exenatide) injection resulted ...

One thing that all sides agree on in the tripartite fight over control of Amylin's board of directors is that the launch of exenatide once weekly, the long-acting version of its diabetes drug Byetta, ...

An update from the NewsMakers in Biotech conference in NYC on an item of intense interest. Amylin Pharmaceuticals just held a well-attended PowerPoint presentation followed by a very cramped breakout ...

Amneal announced the advancement of two key strategic initiatives. Amneal has received approval from the Food and Drug Administration for exenatide, which is the company’s first generic injectable ...